Biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas

Objective: To examine efficacy and safety of biweekly administration of docetaxel and carboplatin for advanced or recurrent endometrial and ovarian carcinomas. Material and Methods: The recommended doses were determined in the phase I study. In the phase II feasibility study, the primary end-point was safety, and the secondary end-point was response rate and progression-free survival (PFS). Results: The recommended doses of docetaxel and carboplatin were determined to be 45 mg/m² and AUC 3.0, respectively, in phase I study. In phase II feasibility study, no treatment-related death was observed. Most non-hematotoxicity cases were mild or moderate. Grade 4 neutropenia was confirmed in 13 patients (31.0%), whereas all cases showed tolerability with 2.6 days delay of anticancer drugs administration in both groups. Response rate was 55.0% in the ovarian carcinoma group, and average PFS was 8.7 months. In the endometrial carcinoma group, response rate was 50.0% and average PFS was 32.0 months. Conclusion: The present results showed that biweekly administration of docetaxel and carboplatin for advanced and recurrent endometrial and ovarian carcinomas results in acceptable side effects, response rate, and PFS.

Biweekly administration; Docetaxel; Carboplatin; Endometrial carcinoma; Ovarian carcinoma.

[1] Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al.: “Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study”. J. Clin. Oncol., 2003, 21, 3194.

[2] Akram T., Maseelall P., Fanning J. : “Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer”. Am. J. Obstet. Gynecol., 2005, 192, 1365.

[3] Hoskins P.J., Swenerton K.D., Pike J.A., Wong F., Lim P., Acquino- Parsons C., et al.: “Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study”. J. Clin. Oncol., 2001, 19, 4048.

[4] Michener C.M., Peterson G., Kulp B., Webster K.D., Markman M.: “Carboplatin plus paclitaxel in the treatment of advanced or recurrent endometrial carcinoma”. J. Cancer Res. Clin. Oncol., 2005, 131, 581.

[5] Ishii Y., Fujimoto S., Okazaki K., Miyoshi M., Furihata T., Hase I., et al.: “Fractionated administration of carboplatin/paclitaxel reduces neurotoxicity in patients with advanced non-small cell lung cancer”. Anticancer Drugs, 2011, 22, 926.

[6] Wasserheit C., Frazein A., Oratz R., Sorich J., Downey A., Hochster H., et al.: “Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity”. J. Clin. Oncol., 1996, 14, 1993.

[7] Vasey P.A., Jayson G.C., Gordon A., Gabra H., Coleman R., Atkinson R., et al.: “Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma”. J. Natl. Cancer Inst., 2004, 96, 1682.

[8] Pignata S., Breda E., Scambia G., Pisano C., Zagonel V., Lorusso D., et al.: “A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study”. Crit. Rev. Oncol. Hematol., 2008, 66, 229.

[9] Sehouli J., Stengel D., Elling D., Ortmann O., Blohmer J., Riess H., et al.: “First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study”. Gynecol. Oncol., 2002, 85, 321.

[10] Sehouli J., Stengel D., Mustea A., Camara O., Keil E., Elling D., et al.: “Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO”. Cancer Chemother. Pharmacol., 2008, 61, 243.

[11] Vandenput I., Vergote I., Neven P., Amant F.: “Weekly paclitaxelcarboplatin regimen in patients with primary advanced or recurrent endometrial carcinoma”. Int. J. Gynecol. Cancer, 2012, 22, 617.

[12] Ishimoto O., Sugawara S., Inoue A., Ishida T., Munakata M., Koinumaru S., et al.: “Phase II study of carboplatin combined with biweekly docetaxel for advanced non-small cell lung cancer”. J. Thorac. Oncol., 2006, 1, 979.

[13] Sakai H., Yoneda S., Kobayashi K., Komagata H., Kosaihira S., Kazumoto T., et al.: “Phase II study of bi-weekly docetaxel and carboplatin with concurrent thoracic radiation therapy followed by consolidation chemotherapy with docetaxel plus carboplatin for stage III unresectable non-small cell lung cancer”. Lung Cancer, 2004, 43, 195.

[14] Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf

[15] Rustin G.J., Timmers P., Nelstrop A., Shreeves G., Bentzen S.M., Baron B., et al.: “Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide”. J. Clin. Oncol., 2006, 24, 45.

[16] Ball H.G., Blessing J.A., Lentz S.S., Mutch D.G.: “A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study”. Gynecol. Oncol., 1996, 62, 278.

[17] Lincoln S., Blessing J.A., Lee R.B., Rocereto T.F.: “Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol. , 2003, 88, 277.

[18] Günthert A.R., Ackermann S., Beckmann M.W., Camara O., Kiesel L., Rensing K., et al.: “Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4”. Gynecol. Oncol., 2007, 104, 86.

[19] Katsumata N., Noda K., Nozawa S., Kitagawa R., Nishimura R., Yamaguchi S., et al.: “Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study”. Br. J. Cancer, 2005, 93, 999.

[20] Hamed R.H., Abdelkhalek S.E.: “Clinical outcome of docetaxel in advanced or metastatic endometrial cancer”. Hematol. Oncol. Stem Cell Ther., 2012, 5, 146.

[21] Tropé C., Johnsson J.E., Simonsen E., Christiansen H., Cavallin- Ståhl E., Horváth G.: “Treatment of recurrent endometrial adenocarcinoma with a combination of doxorubicin and cisplatin”. Am. J. Obstet. Gynecol., 1984, 149, 379.

[22] Dunton C.J., Pfeifer S.M., Braitman L.E., Morgan M.A., Carlson J.A., Mikuta J.J.: “Treatment of advanced and recurrent endometrial cancer with cisplatin, doxorubicin, and cyclophosphamide”. Gynecol. Oncol., 1991, 41, 113.

[23] Aapro M.S., van Wijk F.H., Bolis G., Chevallier B., van der Burg M.E., Poveda A., et al.: “Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group”. Ann. Oncol., 2003, 14, 441.

[24] Thigpen J.T., Brady M.F., Homesley H.D., Malfetano J., DuBeshter B., Burger R.A., et al.: “Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study”. J. Clin. Oncol., 2004. 22, 3902.

[25] Fleming G.F., Brunetto V.L., Cella D., Look K.Y., Reid G.C., Munkarah A.R., et al.: “Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study”. J. Clin. Oncol., 2004, 22, 2159.

[26] Theodoulou M., Seidman A.D.: “Cardiac effects of adjuvant therapy for early breast cancer”. Semin. Oncol., 2003, 30, 730.

[27] Ringel I., Horwitz S.B.: “Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol”. J. Natl. Cancer Inst., 1991, 83, 288.

[28] Strauss H.G., Henze A., Teichmann A., Karbe I., Baumgart A., Thomssen C., et al.: “Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer”. Gynecol. Oncol., 2007, 104, 612.

[29] Nomura H., Aoki D., Takahashi F., Katsumata N., Watanabe Y., Konishi I., et al.: “Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)”. Ann. Oncol., 2011, 22 ,636.